Open PositionsBack to Open Positions
Senior/Principal Chemical Biologist
We are looking for a senior/principal chemical biologist!
We are looking for you!
You are a proactive and creative chemical biologist who can work collaboratively and communicate effectively with colleagues across scientific disciplines and functions. Working with Cedilla’s novel proteomics platform, you will contribute to iterative experimental design and mechanistic hypotheses generation through the interpretation of complex data that will lead to new insights into the molecular mechanism of action for protein targets and candidate therapeutic chemical entities.
With a strong desire for developing and executing on strategies aimed at fundamental understanding of biology, you will work closely with other Cedilla scientists to identify and characterize novel oncology targets and their modulators.
We view you as a important thought partner in the company and you will contribute in countless ways. Your contributions will include:
- Contributing to the identification and characterization of novel protein-ligand and protein-protein interactions from therapeutically significant biological samples using state-of-the-art methods.
- Developing and using chemical biology probes and workflows to explore the proteome and the mechanisms that govern protein homeostasis.
- Working closely with proteomics biochemistry and biophysics scientists, cell biologists and medicinal chemists to support the discovery and functional validation of novel drug targets (TIDVal), interrogate cell genotype-phenotype-proteotype correlations and characterize the mechanism of action (MoA) and in-cell engagement of protein homeostasis modulators.
Highlights of your background include:
- Proven track record in the implementation of diverse chemical biology and chemo-proteomics workflows and experiments applied to study small molecule-protein and protein-protein interactions, MoA studies and TIDVal. Hands-on experience using affinity and/or activity-based proteomic profiling both for in-lysate, in-tissue and whole-cell workflows.
- Demonstrated evidence of creative and independent scientific thinking to solve complex technical and scientific problems. Capable of integrating information generated from multiple sources to shape and strengthen experimental design and research hypotheses.
- Expertise in synthetic, bio-compatible and biorthogonal chemistry methods and medicinal chemistry principles for structure-activity relationship (SAR) optimization applied towards the design and selection of chemical biology probes, affinity- and activity-based proteome enrichment baits (i.e. SMs, ABPPs, substrates and metabolites, peptides, etc.). Prior experience in hit-to-lead optimization applied to drug discovery programs is a plus.
- General understanding of quantitative high-resolution mass spectrometry (qHRMS) proteomics experimentation and its diverse, multiplexed workflows. Hands-on experience in sample processing is preferred.
- Experience managing external collaborations and working with third parties, academic and contract research partners, is highly desirable.
- Highly self-motivated, with excellent attention to detail and strong organizational and communication (oral and written) skills. Ability to work independently, yet team-oriented and capable of mentoring junior team members, building strong relationships with peers, customers and partners/collaborators.
- Degree in biochemistry, chemical biology or equivalent with 10+ years of experience, with a focus on synthetic and medicinal chemistry, applied to chemical biology and chemo-proteomics.
You are not just an amazing CHEMICAL BIOLOGIST, you’re the whole package!
Cedilla is leveraging a growing understanding of the principles that dictate protein stability and applying those principles to target proteins that drive cancer and other diseases. Cedilla’s integrated product engine includes target-centric and unbiased approaches and is designed to produce small molecule therapeutics that degrade protein targets. Although degradation by small molecules has been observed serendipitously, degradation as a mechanism of action has not been pursued systematically in small molecule drug discovery.
We were launched in April 2018 and are backed by Third Rock Ventures